Comparing Lucentis vs Vabysmo
| Lucentis (ranibizumab) | Vabysmo (faricimab) |
|
|---|
| Lucentis (ranibizumab) | Vabysmo (faricimab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, Myopic Choroidal Neovascularization, Macular Edema. Lucentis may... View more |
Prescription only
Prescribed for Macular Edema Following Retinal Vein Occlusion, Macular Degeneration, Diabetic Macular Edema, Macular Edema. Vabysmo may also be used for purposes not listed in this medication guide. |
Related suggestions Macular Degeneration
Diabetic Macular Edema
Macular Edema
Macular Edema Following Retinal Vein Occlusion
Popular comparisons
|
|||||||||||||||
| More about Lucentis (ranibizumab) | More about Vabysmo (faricimab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Lucentis has an average rating of 6.3 out of 10 from a total of 16 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 25% reported a negative effect. |
Vabysmo has an average rating of 7.7 out of 10 from a total of 38 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 5% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Lucentis side effects |
View all Vabysmo side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Lucentis prices |
View all Vabysmo prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other ranibizumab brands include: Byooviz, Cimerli, Susvimo |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
216 hours |
180 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 2 drugs are known to interact with Lucentis:
|
A total of 20 drugs are known to interact with Vabysmo:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
N/A |
January 28, 2022 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.